New Schizophrenia Drug Tested in Russia

21 November 2019

GMP News

The Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences conducts clinical trials of a remedy for schizophrenia, manic-depressive syndrome and other anxiety disorders, said Maxim Korolev, deputy head of the ICG branch.

“This drug is currently in the phase of clinical trials,” - he said.

As previously reported, a preparation based on lithium salts and aluminum oxide has a beneficial effect on the serotonin system and has successfully passed tests in mice.

A preclinical test for ischemic stroke is also underway, he said.

Korolev noted that the effect is achieved due to the fact that the molecule can emit nitric oxide – it is this compound that dilates blood vessels, while the drug can enter the cell.

In addition, said Korolev, the same molecule can be a means of delivering other drugs to the body.

According to him, preliminary data indicate that the drug is not toxic.

“So far the data, let’s say, are optimistic,” - he said.

According to him, the preclinical phase will last about two years.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more